Johnson & Johnson Discloses Second-Quarter and Six-Month Sales and Earnings Results for Period Ended June 28, 2026

Johnson & Johnson Reports Second-Quarter 2026 Financial Results

Johnson & Johnson disclosed on July 15, 2026, that it had issued a press release announcing its sales and earnings for the fiscal second quarter ended June 28, 2026. The company confirmed the results under Item 2.02 of its current report, which covers results of operations and financial condition. The disclosure was signed on behalf of the registrant by Robert J. Decker, Jr., the company's Controller and Principal Accounting Officer.

The filing confirms that the press release was attached as Exhibit 99.1, while Exhibit 99.2 provides unaudited comparative supplementary sales data and a condensed consolidated statement of earnings covering both the fiscal second quarter and the six-month period. The company did not disclose specific revenue figures, earnings per share, or segment-level results within the body of the current report itself; those figures are contained within the attached exhibits referenced in the disclosure.

Six-Month Comparative Financial Data Included Alongside Quarterly Results

In addition to the quarterly results, the disclosure confirms that Johnson & Johnson has provided unaudited comparative supplementary sales data covering the first six months of the company's fiscal year. This supplementary data, included as Exhibit 99.2, presents a condensed consolidated statement of earnings alongside the sales information for the six-month period ending June 28, 2026. The inclusion of a six-month comparative dataset provides a broader view of the company's financial trajectory through the first half of its fiscal year.

The filing does not summarize the specific contents of the exhibits within the body of the current report. As a result, individual revenue figures by business segment, gross profit margins, and other line-item financial metrics are not reproduced within the current report narrative itself. Readers and stakeholders seeking those details are directed to the referenced exhibits as described in the company's disclosure.

Johnson & Johnson's Common Stock and NYSE Listing Details

The disclosure confirms that Johnson & Johnson's common stock, with a par value of $1.00 per share, is listed and traded on the New York Stock Exchange under the trading symbol JNJ. The company is incorporated in the state of New Jersey and maintains its principal executive offices at One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933. The registrant's IRS Employer Identification Number is listed as 22-1024240 in the filing.

The company is identified as a non-emerging growth company in the disclosure, meaning it is not eligible for extended transition periods for complying with new or revised financial accounting standards under applicable Securities Exchange Act provisions. This classification reflects Johnson & Johnson's status as a long-established, large-cap registrant subject to standard reporting requirements and timelines.

Ten Series of Exchange-Listed Notes Spanning 2028 to 2055

The disclosure lists ten separate series of notes issued by Johnson & Johnson that are registered under Section 12(b) of the Securities Exchange Act and listed on the New York Stock Exchange. These notes carry coupon rates ranging from 1.150% to 3.700% and mature at various dates between November 2028 and February 2055, as specified in the filing. Each series carries its own distinct trading symbol on the NYSE.

The ten listed note series, as disclosed in the filing, are as follows: 1.150% Notes Due November 2028 (JNJ28); 2.700% Notes Due February 2029 (JNJ29B); 3.200% Notes Due June 2032 (JNJ32); 3.050% Notes Due February 2033 (JNJ33B); 1.650% Notes Due May 2035 (JNJ35); 3.350% Notes Due June 2036 (JNJ36A); 3.350% Notes Due February 2037 (JNJ37B); 3.550% Notes Due June 2044 (JNJ44); 3.600% Notes Due February 2045 (JNJ45); and 3.700% Notes Due February 2055 (JNJ55). All ten series are confirmed as listed on the New York Stock Exchange in this disclosure.

Note Maturities Reflect Johnson & Johnson's Long-Duration Debt Profile

The range of maturity dates across Johnson & Johnson's listed notes — spanning from 2028 through 2055 — reflects a debt structure with obligations distributed across multiple decades, as documented in the filing. The earliest maturing listed notes are the 1.150% Notes Due November 2028, while the longest-duration instrument is the 3.700% Notes Due February 2055, representing a roughly 29-year span between the nearest and furthest maturities disclosed.

The coupon rates on these notes, as listed in the filing, vary from a low of 1.150% on the November 2028 notes to a high of 3.700% on the February 2055 notes. The filing does not provide the outstanding principal balance for any individual note series, nor does it disclose aggregate long-term debt figures within the body of the current report. The company did not disclose this figure in the filing.

Robert J. Decker, Jr. Signs Report as Principal Accounting Officer

The current report was executed and signed on July 15, 2026, by Robert J. Decker, Jr., identified in the filing as the company's Controller and Principal Accounting Officer. His signature confirms that the disclosure was duly authorized on behalf of Johnson & Johnson as the registrant. The filing does not include signatures or certifications from the Chief Executive Officer or Chief Financial Officer within the body of this particular current report.

The report confirms that none of the applicable boxes under the written communications, soliciting material, or pre-commencement communications provisions were checked, indicating the disclosure does not simultaneously satisfy any alternative filing obligations under the Securities Act or the Exchange Act beyond the standard current report requirement. This is consistent with a routine earnings-related current report disclosure.

Filing Covers Item 2.02 — Results of Operations and Financial Condition

The disclosure falls under Item 2.02 of the applicable reporting requirements, which governs results of operations and financial condition. Under this item, registrants are required to disclose material information regarding their financial results when that information is released publicly. Johnson & Johnson satisfied this requirement by attaching the press release as Exhibit 99.1 to the current report filed on July 15, 2026.

Item 9.01 of the filing, covering financial statements and exhibits, lists three exhibits in total: Exhibit 99.1, which is the press release dated July 15, 2026; Exhibit 99.2, which contains the unaudited comparative supplementary sales data and condensed consolidated statement of earnings for the fiscal second quarter and six-month period; and Exhibit 104, which is the cover page formatted in Inline XBRL as required for current reports. The filing does not include full audited financial statements within the current report itself.

Johnson & Johnson's Corporate Structure and Registrant Details

Johnson & Johnson is incorporated in the state of New Jersey and holds Commission File Number 1-3215 as assigned by the applicable regulatory authority. The company's CIK number is listed as 0000200406 in the filing. These identifiers confirm that this disclosure relates to the parent Johnson & Johnson entity, which operates across pharmaceutical, medical technology, and related healthcare segments, as the company has publicly described its business in prior disclosures.

The company's principal executive offices remain at One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933, with a registrant telephone number of 732-524-0400, as stated in the filing. These details are consistent with Johnson & Johnson's status as one of the largest healthcare companies listed on a major U.S. exchange, operating globally across multiple business lines including innovative medicine and MedTech, as the company has described in its public filings.

Exhibit 99.2 Provides Unaudited Supplementary Sales Data for Both Periods

The inclusion of Exhibit 99.2 alongside the press release is notable because it provides unaudited comparative supplementary sales data in addition to the condensed consolidated statement of earnings. This type of supplementary data typically allows for period-over-period comparisons across product lines and geographic segments, though the current report itself does not describe the specific contents or line items contained within that exhibit.

The filing characterizes this data as unaudited, which is standard for interim quarterly and half-year financial disclosures prior to year-end audit completion. The supplementary nature of the data, as described in the filing, suggests it provides additional granularity beyond the primary press release figures, though the specific breakdown by segment or geography is not reproduced within the body of the current report. The company did not disclose specific financial metrics from the exhibit within the current report narrative.

Share Price and Market Reaction Following the Earnings Disclosure

The immediate share price impact of this earnings disclosure was not clear from available public information at the time this article was prepared. The filing itself does not reference any share price movement, market guidance, or forward-looking financial targets within the body of the current report. Any market reaction would be reflected in subsequent trading activity on the New York Stock Exchange, where JNJ common stock is listed.

The disclosure confirms that Johnson & Johnson is not an emerging growth company, meaning the company is subject to the full scope of reporting and disclosure obligations applicable to established large-cap registrants. No guidance figures, updated full-year financial forecasts, or commentary on business conditions were included within the body of the current report as filed on July 15, 2026.